Drugs and Diagnostics for Hematological Disorders: Global Markets
상품코드:1517519
리서치사:BCC Research
발행일:2024년 07월
페이지 정보:영문 133 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 혈액 질환용 치료제 및 진단약 시장 규모는 2024년 1,312억 달러에서 예측 기간 중 CAGR 7.6%로 추이하며, 2029년말에는 1,893억 달러에 달할 것으로 예측됩니다.
북미 지역은 2024년 589억 달러에서 CAGR 7.8%로 추이하며, 2029년말까지 857억 달러에 달할 것으로 예측됩니다. 또한 유럽 지역은 2024년 341억 달러에서 CAGR 7.0%로 추이하며, 2029년말에는 478억 달러에 달할 것으로 예측됩니다.
세계의 혈액 질환용 치료제 및 진단약 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 신규 기술 및 기술개발 동향, 시장 규모 추이·예측, 각종 구분·지역별 상세 분석, 경쟁 구도, 주요 기업의 개요 등을 정리하여 전해드립니다.
목차
제1장 개요
시장 전망
조사 범위
시장 개요
제2장 시장 개요
개요
PESTEL 분석
Porter's Five Forces 분석
혈액검사 기기 공급망과 물류
제3장 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
제4장 의약품 특허 상황과 최근 개발 상황
특허 상황
신규 승인
제5장 신규 기술과 개발
개요
신기술
AI 지원 진단
차세대 시퀀싱(NGS)
마이크로플루이딕스와 랩온어칩 디바이스
유전자 치료
면역치료
임상시험
제6장 시장 세분화 분석
세분화 내역
시장별 분류
혈액 질환 진단 시장
혈액 질환 진단 시장 : 제품 유형별
혈액 질환 진단 시장 : 최종사용자별
혈액학 의약품 시장
혈액학 의약품 시장 : 의약품 유형별
지역 목표 내역
북미
유럽
아시아태평양
기타 지역
제7장 경쟁 정보
주요 기업
혈액 질환 진단약
혈액 질환 치료제
희소 혈액 질환 치료제의 새로운 개발자
제8장 부록
조사 방법
전시
약어
기업 개요
ABBOTT
AMGEN INC.
BIO-RAD LABORATORIES INC.
BRISTOL MYERS SQUIBB CO.
DANAHER CORP.
F. HOFFMANN-LA ROCHE LTD.
NOVARTIS AG
SANOFI
SYSMEX CORP.
TAKEDA PHARMACEUTICAL CO. LTD.
KSA
영문 목차
영문목차
The global market for drugs and diagnostics for hematological disorders is expected to grow from $131.2 billion in 2024 and is projected to reach $189.3 billion by the end of 2029, at a compound annual growth rate (CAGR) of 7.6% during the forecast period of 2024 to 2029.
The North American market for drugs and diagnostics for hematological disorders is expected to grow from $58.9 billion in 2024 and is projected to reach $85.7 billion by the end of 2029, at a CAGR of 7.8% during the forecast period of 2024 to 2029.
The European market for drugs and diagnostics for hematological disorders is expected to grow from $34.1 billion in 2024 and is projected to reach $47.8 billion by the end of 2029, at a CAGR of 7.0% during the forecast period of 2024 to 2029.
Report Scope
This report covers the worldwide market for the drugs used to treat hematological disorders, as well as the devices and reagents used to diagnose these diseases. Based on product type, the diagnostic market for hematological disorders is divided into reagents & instruments and software. By end user, the market is segmented into hospitals, diagnostic labs, and others. On the basis of drug type, the drugs used to treat hematological disorders are divided into oncology drugs and non-oncology drugs.
The market is divided into four geographic regions: North America, Europe, Asia-Pacific, and Rest of the World (RoW). For market estimates, data has been provided for 2023 as the base year, with forecasts for 2024 through 2029. The report also covers approved drugs, the pipeline analysis, innovative research, opportunities within the market, and profiles of leading companies.
The growing number of individuals with leukemia is the main reason for the market's growth and the development of more effective drugs.
Report Includes
49 data tables and 44 additional tables
An overview of the current and future global markets for drugs and diagnostics for hematological disorders
Analyses of the global market trends, with market revenue data for 2021-2023, estimates for 2024, forecasts for 2029, and projected CAGRs through 2029
Estimate of the current market size and revenue growth prospects, along with a market share analysis by segment, product, end user, drug type, and region
Facts and figures pertaining to the market dynamics, current and emerging technologies, regulations, cancer incidence, and the impact of various macroeconomic factors
A look at treatment strategies, such as hematological therapeutics and drugs, chemotherapy, radiotherapy and immunotherapy, as well as testing and screening methods for diagnosis
Review of technological developments, product introductions, and other recent industry activity of the major players
Discussion of sustainability trends and ESG developments in the industry, with a focus on consumer attitudes, companies' ESG score rankings and their ESG practices
An analysis of recent patents
A look at the competitive landscape, including companies' market shares, M&A activity and venture funding
Profiles of the leading market players, including Danaher, Abbott, Sysmex Corp., Bristol Myers Squibb Co., and F. Hoffmann-La Roche Ltd.
Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
PESTEL Analysis
Political
Economic
Social
Technological
Environmental
Legal
Porter's Five Forces Analysis
Bargaining Power of Buyers
Bargaining Power of Suppliers
Potential of New Entrants
Threat of Substitutes
Competition in the Industry
Supply Chain and Logistics for Hematological Instruments
Chapter 3 Market Dynamics
Market Drivers
Incidence of Blood Disorders
Rising Use of Automation
Diagnosis of Hematology Disorders
Increasing Government and Private Funding for Treatment
Market Restraints
High Cost of Instruments
High Cost of Treatment
Reimbursement Challenges for Physicians
Market Opportunities
Rising Health Awareness
Emerging Economies
Chapter 4 Patent Landscape and Current Developments in Drugs
Patent Landscape
New Approvals
Chapter 5 Emerging Technologies and Developments
Overview
Emerging Technologies
AI-Assisted Diagnosis
Next-Generation Sequencing (NGS)
Microfluidics and Lab-on-a-Chip Devices
Gene Therapies
Immunotherapies
Clinical Trials
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Segmentation by Market
Hematological Disorders Diagnostics Market
Hematological Disorders Diagnostic Market, By Product Type
Hematological Disorders Diagnostic Market, By End User
Hematology Drug Market
Hematology Drug Market, By Drug Type
Geographic Breakdown
North America
Europe
Asia-Pacific
Rest of the World
Chapter 7 Competitive Intelligence
Leading Companies
Hematological Disorder Diagnostics
Hematological Disorder Drugs
New Developers of Drugs for Rare Hematology Disorders
